Publications (26)125.51 Total impact
-
Article: H5N1 Hybrid Viruses Bearing 2009/H1N1 Virus Genes Transmit in Guinea Pigs by Respiratory Droplet.
[show abstract] [hide abstract]
ABSTRACT: In the past, avian influenza viruses have crossed species' barriers to trigger human pandemics by reassorting with mammal-infective viruses in intermediate livestock hosts. H5N1 viruses are able to infect pigs, and some of them have affinity for the mammalian type α-2,6-linked sialic acid airway receptor. By using reverse genetics, we systemically created 127 reassortant viruses between a duck isolate of H5N1, specifically retaining its hemagglutinin (HA) gene throughout, and a highly transmissible, human-infective H1N1 virus. We tested the virulence of the reassortants in mice as a correlate for virulence in humans, and tested transmissibility in guinea pigs, which have both avian and mammalian types of airway receptor. Transmission study showed that both polymerase PA gene and nonstructural protein NS gene of H1N1 virus made the H5N1 virus transmissible by respiratory droplet between guinea pigs, without death. Further experiments implicated other H1N1 genes in the enhancement of mammal-to-mammal transmission, including nucleoprotein (NP), neuraminidase (NA), and matrix (M), as well as mutations in H5 HA that improve affinity for human-like airway receptors. Hence, avian H5N1 subtype viruses do have the potential to acquire mammalian transmissibility by reassortment in current agricultural scenarios.Science 05/2013; · 31.20 Impact Factor -
Article: A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks.
[show abstract] [hide abstract]
ABSTRACT: Ducks play an important role in the maintenance of highly pathogenic H5N1 avian influenza viruses (AIVs) in nature, and the successful control of AIVs in ducks has important implications for the eradication of the disease in poultry and its prevention in humans. The inactivated influenza vaccine is expensive, labor-intensive, and usually needs 2 to 3 weeks to induce protective immunity in ducks. Live attenuated duck enteritis virus (DEV; a herpesvirus) vaccine is used routinely to control lethal DEV infections in many duck-producing areas. Here, we first established a system to generate the DEV vaccine strain by using the transfection of overlapping fosmid DNAs. Using this system, we constructed two recombinant viruses, rDEV-ul41HA and rDEV-us78HA, in which the hemagglutinin (HA) gene of the H5N1 virus A/duck/Anhui/1/06 was inserted and stably maintained within the ul41 gene or between the us7 and us8 genes of the DEV genome. Duck studies indicated that rDEV-us78HA had protective efficacy similar to that of the live DEV vaccine against lethal DEV challenge; importantly, a single dose of 10(6) PFU of rDEV-us78HA induced complete protection against a lethal H5N1 virus challenge in as little as 3 days postvaccination. The protective efficacy against both lethal DEV and H5N1 challenge provided by rDEV-ul41HA inoculation in ducks was slightly weaker than that provided by rDEV-us78HA. These results demonstrate, for the first time, that recombinant DEV is suitable for use as a bivalent live attenuated vaccine, providing rapid protection against both DEV and H5N1 virus infection in ducks.Journal of Virology 08/2011; 85(21):10989-98. · 5.40 Impact Factor -
Article: Strategies for improving the efficacy of a H6 subtype avian influenza DNA vaccine in chickens.
[show abstract] [hide abstract]
ABSTRACT: A low-pathogenicity avian influenza H6N2 virus was used to investigate approaches to improve DNA vaccine efficacy. The viral hemagglutinin (HA) gene or its chicken biased HA gene, incorporating a Kozak sequence, was cloned into a pCAGGS vector to produce the pCAG-HAk and pCAG-optiHAk constructs. Following two intramuscular injections, the seroconversion rate in vaccinated chickens with 10, 100 or 300 μg pCAG-HAk were 87.5%, 75% and 75%, respectively. The profile of H6 hemagglutination inhibition (HI) antibodies induced by different doses of pCAG-HAk during the 8-week study period was similar. The HI titer rose significantly in the three different dose groups following the booster and reached a plateau 2-3 weeks post-booster. In a single dose vaccination group with 100 μg pCAG-HAk, a maximum seroconversion rate reached 53.3% at 5 weeks post-vaccination. The earliest time of seroconversion appeared two weeks after DNA immunization. Following two electroporation (EP) vaccinations with 100 μg pCAG-HAk, all birds seroconverted and the HI antibody titers were significantly higher than those using intramuscular immunization, suggesting that EP was more efficient than intramuscular delivery of the DNA vaccines. In comparison, chickens immunized with 10 or 100 μg pCAG-optiHAk showed 37.5% and 87.5% seroconversion rates, respectively, at 3 weeks following the booster. The pCAG-HAk was not significantly different from the pCAG-optiHAk in either the seroconversion rate or H6 HI titer, suggesting that the codon-optimized HA DNA vaccine did not achieve significantly better immunogenicity than the pCAG-HAk vaccine.Journal of virological methods 02/2011; 173(2):220-6. · 2.13 Impact Factor -
Article: New avian influenza virus (H5N1) in wild birds, Qinghai, China.
[show abstract] [hide abstract]
ABSTRACT: Highly pathogenic avian influenza virus (H5N1) (QH09) was isolated from dead wild birds (3 species) in Qinghai, China, during May-June 2009. Phylogenetic and antigenic analyses showed that QH09 was clearly distinguishable from classical clade 2.2 viruses and belonged to clade 2.3.2.Emerging Infectious Diseases 02/2011; 17(2):265-7. · 6.79 Impact Factor -
Article: Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009.
[show abstract] [hide abstract]
ABSTRACT: Despite substantial efforts to control H5N1 avian influenza viruses (AIVs), the viruses have continued to evolve and cause disease outbreaks in poultry and infections in humans. In this report, we analyzed 51 representative H5N1 AIVs isolated from domestic poultry, wild birds, and humans in China during 2004 to 2009, and 21 genotypes were detected based on whole-genome sequences. Twelve genotypes of AIVs in southern China bear similar H5 hemagglutinin (HA) genes (clade 2.3). These AIVs did not display antigenic drift and could be completely protected against by the A/goose/Guangdong/1/96 (GS/GD/1/96)-based oil-adjuvanted killed vaccine and recombinant Newcastle disease virus vaccine, which have been used in China. In addition, antigenically drifted H5N1 viruses, represented by A/chicken/Shanxi/2/06 (CK/SX/2/06), were detected in chickens from several provinces in northern China. The CK/SX/2/06-like viruses are reassortants with newly emerged HA, NA, and PB1 genes that could not be protected against by the GS/GD/1/96-based vaccines. These viruses also reacted poorly with antisera generated from clade 2.2 and 2.3 viruses. The majority of the viruses isolated from southern China were lethal in mice and ducks, while the CK/SX/2/06-like viruses caused mild disease in mice and could not replicate in ducks. Our results demonstrate that the H5N1 AIVs circulating in nature have complex biological characteristics and pose a continued challenge for disease control and pandemic preparedness.Journal of Virology 09/2010; 84(17):8389-97. · 5.40 Impact Factor -
Article: Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine.
[show abstract] [hide abstract]
ABSTRACT: Infection with H9 avian influenza virus (AIV) and Newcastle disease virus (NDV) are two important causes of egg drop in layer and breeder poultry, leading to severe economic loss in the industry. Currently in China, inactivated H9 AIV vaccine and live attenuated NDV vaccine have to be repeatedly administered to prevent egg drop in layer animals. Using reverse genetics, we constructed a recombinant NDV expressing an H9 AIV hemagglutinin (HA) from an H9N2 field isolate, A/Chicken/ Shandong/2/2007. The HA gene was inserted into the intergenic region between the phosphoprotein (P) and matrix (M) genes of the LaSota NDV vaccine strain. The recombinant virus stably expressing the HA gene, rL-H9, was found to be innocuous after intracerebral inoculation of 1-day-old chickens. A single dose of 10(6) 50% egg infectious dose of the recombinant virus intranasally inoculated into chickens induced high levels of NDV- and AIV H9-specific hemagglutination-inhibition antibody. Complete protection from clinical disease and mortality against challenge with a lethal dose of velogenic NDV was observed in chickens and 90% of chickens were protected from clinical disease, mortality, and virus shedding against challenge with homologous H9N2 AIV. Our results suggest that recombinant NDV is suitable as a potential bivalent live attenuated vaccine against both NDV and H9 AIV infection in poultry.Avian Diseases 03/2010; 54(1 Suppl):294-6. · 1.46 Impact Factor -
Article: Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam.
[show abstract] [hide abstract]
ABSTRACT: An inactivated H5N1 avian influenza (AI) vaccine generated by reverse genetics and containing the hemagglutinin and neuraminidase genes of the H5N1 A/goose/Guangdong/1/96 (GS/GD/06) virus has been used in domestic poultry in China and Vietnam as an important control strategy for H5N1 AI. The efficacy of this vaccine against early H5N1 isolates has been fully evaluated in chicken, ducks, and geese. However, there are no reports about its efficacy against H5N1 viruses recently isolated in China and Vietnam. In this study, groups of 3-wk-old specific-pathogen-free chickens were intramuscularly injected with one dose of the vaccine. Three weeks postvaccination, the chickens were intranasally challenged with 10(5)EID50 of six different lethal H5N1 AI viruses: A/bar-headed goose/Qinghai/3/05 (clade 2.2), A/chicken/Shanxi/2/06 (CK/SX/06; clade 7), A/duck/Fujian/31/07 (clade 2.3.4), A/MDK/VN-HD/46/07 (clade 2.3.4), A/MDK/VN-CM/1185/06 (clade 1), and A/MDK/VN-CM/1159/06 (clade 1). Four out of 20 chickens challenged with the CK/SX/06 shed virus on day 5 and died on day 8 to 9 postchallenge. Chickens challenged with the remaining five viruses were completely protected (no disease signs, virus shedding, or deaths). These results indicate that the GS/GD/06-based vaccine provides sound protection against clade 1, 2.2, and 2.3.4 viruses, but not against the CK/SX/06 virus, which emerged in northern China in 2006.Avian Diseases 03/2010; 54(1 Suppl):287-9. · 1.46 Impact Factor -
Article: Protective efficacy of H7 subtype avian influenza DNA vaccine.
[show abstract] [hide abstract]
ABSTRACT: Highly pathogenic avian influenza viruses (HPAIV) have historically caused disastrous damage to the poultry industry, and recently they have shown their zoonotic potential by causing human infections and deaths. Control and prevention of HPAIV are therefore important issues for both veterinary and human public health. In this study, we constructed a plasmid, pCAGGoptiH7, encoding a codon-optimized HA gene of the H7N1 avian influenza virus A/FPV/Rostock/34 (RK/34). To evaluate the vaccine efficacy of pCAGGoptiH7, groups of specific-pathogen-free (SPF) chickens were intramuscularly inoculated with one or two doses of 100 microg, 50 microg, or 10 microg of the plasmid in 3-wk intervals. Four weeks after the single vaccination or 2 wk after the second dose, all chickens were challenged with 100CLD50 (chicken lethal dose) of highly pathogenic RK/34. After the single dose vaccination, only 90% of chickens were protected in all of the pCAGGoptiH7-immunized groups, although all of the chickens immunized generated detectable HI antibodies. After the second dose of vaccination, HI antibodies increased sharply, and chickens in the 100-microg and 50-microg pCAGGoptiH7-immunized groups were completely protected from virus challenge (no disease signs, no virus shedding, and no deaths). Low titers of virus shedding were detected in two out of ten chickens inoculated with two doses of 10-microg pCAGGoptiH7, although no disease or death was observed. These results provide a strong argument for the continued evaluation of this vaccine in field trials.Avian Diseases 03/2010; 54(1 Suppl):290-3. · 1.46 Impact Factor -
Article: A protein chip designed to differentiate visually antibodies in chickens which were infected by four different viruses.
[show abstract] [hide abstract]
ABSTRACT: This study aimed to develop a visual protein chip that can differentiate the antibodies induced by avian influenza virus, Newcastle disease virus, infectious bronchitis virus and infectious bursal disease virus, simultaneously. Proteins from the four viruses were purified and spotted onto an aldehyde group-modified glass slide at 2mg/ml. After that, the protein chip was reacted with the corresponding positive serum against these viruses, hybridized with a colloidal gold-labeled secondary antibody and visualized by silver staining. A diagnostic protein chip was constructed to differentiate antibodies of four poultry diseases This protein chip showed good sensitivity compared with traditional methods, and it was more than 400 times as sensitive as the agar gel precipitin methods used to detect avian influenza and infectious bursal disease. The protein chip was used to test known serum samples of the four poultry diseases and field serum samples. The results showed that this method could hybridize specifically with the corresponding antibodies with strong signals and without cross-hybridization. In conclusion, this protein chip can be used to differentiate the antibodies induced by the four avian viruses.Journal of virological methods 03/2010; 167(2):119-24. · 2.13 Impact Factor -
Article: Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host.
[show abstract] [hide abstract]
ABSTRACT: Since 2003, H5N1 influenza viruses have caused over 400 known cases of human infection with a mortality rate greater than 60%. Most of these cases resulted from direct contact with virus-contaminated poultry or poultry products. Although only limited human-to-human transmission has been reported to date, it is feared that efficient human-to-human transmission of H5N1 viruses has the potential to cause a pandemic of disastrous proportions. The genetic basis for H5N1 viral transmission among humans is largely unknown. In this study, we used guinea pigs as a mammalian model to study the transmission of six different H5N1 avian influenza viruses. We found that two viruses, A/duck/Guangxi/35/2001 (DKGX/35) and A/bar-headed goose/Qinghai/3/2005(BHGQH/05), were transmitted from inoculated animals to naïve contact animals. Our mutagenesis analysis revealed that the amino acid asparagine (Asn) at position 701 in the PB2 protein was a prerequisite for DKGX/35 transmission in guinea pigs. In addition, an amino acid change in the hemagglutinin (HA) protein (Thr160Ala), resulting in the loss of glycosylation at 158-160, was responsible for HA binding to sialylated glycans and was critical for H5N1 virus transmission in guinea pigs. These amino acids changes in PB2 and HA could serve as important molecular markers for assessing the pandemic potential of H5N1 field isolates.PLoS Pathogens 12/2009; 5(12):e1000709. · 9.13 Impact Factor -
Article: Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.
[show abstract] [hide abstract]
ABSTRACT: The continued spread of highly pathogenic H5N1 influenza viruses among poultry and wild birds, together with the emergence of drug-resistant variants and the possibility of human-to-human transmission, has spurred attempts to develop an effective vaccine. Inactivated subvirion or whole-virion H5N1 vaccines have shown promising immunogenicity in clinical trials, but their ability to elicit protective immunity in unprimed human populations remains unknown. A cold-adapted, live attenuated vaccine with the hemagglutinin (HA) and neuraminidase (NA) genes of an H5N1 virus A/VN/1203/2004 (clade 1) was protective against the pulmonary replication of homologous and heterologous wild-type H5N1 viruses in mice and ferrets. In this study, we used reverse genetics to produce a cold-adapted, live attenuated H5N1 vaccine (AH/AAca) that contains HA and NA genes from a recent H5N1 isolate, A/Anhui/2/05 virus (AH/05) (clade 2.3), and the backbone of the cold-adapted influenza H2N2 A/AnnArbor/6/60 virus (AAca). AH/AAca was attenuated in chickens, mice, and monkeys, and it induced robust neutralizing antibody responses as well as HA-specific CD4+ T cell immune responses in rhesus macaques immunized twice intranasally. Importantly, the vaccinated macaques were fully protected from challenge with either the homologous AH/05 virus or a heterologous H5N1 virus, A/bar-headed goose/Qinghai/3/05 (BHG/05; clade 2.2). These results demonstrate for the first time that a cold-adapted H5N1 vaccine can elicit protective immunity against highly pathogenic H5N1 virus infection in a nonhuman primate model and provide a compelling argument for further testing of double immunization with live attenuated H5N1 vaccines in human trials.PLoS Pathogens 06/2009; 5(5):e1000409. · 9.13 Impact Factor -
Article: [Construction of a recombinant HVT virus expressing the HA gene of avian influenza virus H5N1 via Rde/ET recombination system].
[show abstract] [hide abstract]
ABSTRACT: In recent years,manipulation of large herpesvirus genomes has been facilitated by using bacterial artificial chromosome (BAC) vectors. We have previously reported the construction of the BAC clones (HVT BACs) of herpesvirus of turkey (HVT). With these BAC clones in hand,we manipulated the genome of HVT by utilizing Red/ET recombination system, and developed a biologically safe live vaccine based on the HVT BACs. In this two-step approach, we first transformed the plasmid pRedET into the DH10B competent cells that carried the HVT BACs,and added inducer L-arabinose into the cells. We prepared the cells into competent cells and electroporated the linear rpsL-neo counter-selection/selection cassette flanked by the 50 bp long homology arms into the cells. So the functional cassette was inserted into the U(S)2 locus. Only colonies carrying the modified BAC would survive Kanamycin selection on the agar plates. The successful integration of the rpsL-neo cassette was monitored by PCR and Streptomycin selection, for the insertion of rpsL-neo cassette cells will become Streptomycin sensitive. Secondly, in the same way, we replaced the rpsL-neo cassette with the hemagglutinin (HA) gene of (HPAIV) A/Goose/ Guangdong/1/96(H5N1) flanked by the same homology arms. Only colonies which lost the rpsL-neo cassette will grow on Streptomycin containing plates. Finally, we obtained many colonies of which the HA gene of the AIV was inserted into the U(S)2 locus to be modified of HVT. And we reconstituted one recombinant virus from transfecting one of these BAC clones DNA into chick embryo fibroblasts (CEFs). We achieved one rescued recombinant virus which designated as rHVT-HA3. The H5 subtype HA gene expression in this recombinant virus rHVT-HA3 was confirmed by immunofluorescence assay.ACTA MICROBIOLOGICA SINICA 02/2009; 49(1):78-84. -
Article: Recombinant fowlpox virus vector-based vaccine completely protects chickens from H5N1 avian influenza virus.
[show abstract] [hide abstract]
ABSTRACT: With the widespread presence of influenza virus H5N1 in poultry and wildlife species, particularly migrating birds, vaccination has become an important control strategy for avian influenza (AI). In this study, the immune efficacy and hemagglutination inhibition (HI) antibody responses induced by a recombinant fowlpox virus (FPV) vector-based rFPV-HA-NA vaccine was evaluated in SPF and commercial chickens. Four-week old SPF chickens vaccinated with one dose of vaccine containing 2 x 10(3) plaque forming units (PFU) of virus were completely protected from H5N1 AI virus 1 week after vaccination, and protective immunity lasted for at least 40 weeks. Two-week old commercial layer chickens were vaccinated with the rFPV-HA-NA vaccine and boosted with the same dose of vaccine following an interval of 18 weeks. The HI antibody titers higher than 4log2 lasted for 52 weeks after the booster immunization. We also examined the efficacy of the rFPV-HA-NA vaccine in SPF chickens administrated by different routes. The results showed that effective application of rFPV-HA-NA vaccine in poultry may be restricted to wing-web puncture, intramuscular or subcutaneous injection. These results demonstrate that the rFPV-HA-NA vaccine is effective in the prevention of infection of H5N1 AI virus.Antiviral research 01/2009; 81(3):234-8. · 3.61 Impact Factor -
Article: Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice.
[show abstract] [hide abstract]
ABSTRACT: A/duck/Guangxi/53/2002 (DKGX/53) and A/duck/Fujian/01/2002 (DKFJ/01) are H5N1 avian influenza viruses that are lethal in chickens. In mice, however, DKFJ/01 is highly pathogenic, whereas DKGX/53 displays low pathogenicity. In this study, we used reverse genetics to demonstrate that two amino acid residues at positions 30 and 215 of the M1 protein of these two viruses are important determinants for pathogenicity in mice. We thus firstly prove the M1 protein contributes to the virulence of H5N1 viruses in mice, and the amino acid residues shown to attenuate the virulence could be targeted in influenza virus candidates for live vaccine development.Virology 01/2009; 384(1):28-32. · 3.35 Impact Factor -
Article: Pathogenicity of Chinese H5N1 highly pathogenic avian influenza viruses in pigeons.
[show abstract] [hide abstract]
ABSTRACT: It has long been thought that pigeons are resistant against H5 highly pathogenic avian influenza (HPAI) viruses. Recently, however, highly pathogenic H5N1 avian influenza viruses have demonstrated distinct biological properties that may be capable of causing disease in pigeons. To examine the susceptibility of domestic pigeons to recent H5N1 viruses, we inoculated pigeons using H5N1 viruses isolated in China from 2002 to 2004. Within 21 days following inoculation, all pigeons had survived and fully recovered from temporary clinical signs. However, seroconversion assays demonstrated that several viruses did in fact establish infection in pigeons and caused a certain amount of viral shedding in the oropharynx and cloaca. There was not, however, a definitive relationship between viral shedding and viral origin. Viruses were also inconsistently isolated from various organs of pigeons in infected groups. Pathological examination revealed that the infection had started as respiratory inflammation and caused the most severe lesions in the brain in later stages. These results indicate that pigeons are susceptible to the more recent Asian H5N1 HPAI and could be a source of infection to other animals, including humans.Archives of Virology 10/2008; 153(10):1821-6. · 2.11 Impact Factor -
Article: Pathogenicity of Chinese H5N1 highly pathogenic avian influenza viruses in pigeons
[show abstract] [hide abstract]
ABSTRACT: It has long been thought that pigeons are resistant against H5 highly pathogenic avian influenza (HPAI) viruses. Recently, however, highly pathogenic H5N1 avian influenza viruses have demonstrated distinct biological properties that may be capable of causing dis-ease in pigeons. To examine the susceptibility of domestic pigeons to recent H5N1 viruses, we inoculated pigeons using H5N1 viruses isolated in China from 2002 to 2004. Within 21 days following inoculation, all pigeons had survived and fully recovered from temporary clinical signs. However, seroconversion assays demonstrated that several viruses did in fact establish infection in pigeons and caused a certain amount of viral shedding in the oropharynx and cloaca. There was not, however, a definitive relationship between viral shedding and viral origin. Viruses were also inconsistently isolated from various organs of pigeons in infected groups. Pathological examination revealed that the infection had started as respiratory inflammation and caused the most severe lesions in the brain in later stages. These results indicate that pigeons are susceptible to the more recent Asian H5N1 HPAI and could be a source of infection to other animals, including humans.2.11. 09/2008; -
Article: H5N1 influenza marker vaccine for serological differentiation between vaccinated and infected chickens.
[show abstract] [hide abstract]
ABSTRACT: Using plasmid-based reverse genetics, we generated a molecularly altered virus, H5N1/PR8-5B19, containing modified HA and NA genes from A/Goose/Guangdong/1/96 (GS/GD/1/96). In the H5N1/PR8-5B19 virus, the HA cleavage site was modified to resemble that of low-pathogenic avian strains and a portion of the NA stalk region was replaced by the immunodominant 5B19 epitope of the S2 glycoprotein of murine hepatitis virus (MHV). H5N1/PR8-5B19 is not lethal to embryonated eggs or chickens. Chickens immunized with the H5N1/PR8-5B19 inactivated vaccine produced high levels of HI antibody and a measurable antibody response against the MHV 5B19 epitope, and were fully protected against subsequent challenge with different highly pathogenic H5N1 avian influenza viruses. H5N1/PR8-5B19 is therefore an attractive marker vaccine candidate, eliciting a strong, protective antibody response and enabling serological discrimination between vaccinated and wild-type virus-infected chickens.Biochemical and Biophysical Research Communications 08/2008; 372(2):293-7. · 2.48 Impact Factor -
Article: Single-amino-acid mutation in the HA alters the recognition of H9N2 influenza virus by a monoclonal antibody.
[show abstract] [hide abstract]
ABSTRACT: We explored the molecular basis of antigenic variation by comparing two H9N2 subtype avian influenza viruses, A/Chicken/Shandong/6/96 (CK/SD/6) and A/Chicken/Guangxi/10/99 (CK/GX/10), that react differently to a monoclonal antibody C/B3. To assess the genetic basis for this antigenic difference, we used reverse genetics to generate a series of chimera and mutants of these two viruses. We found that a single-amino-acid substitution of asparagine for serine at position 145 (S145N) in the HA protein prevents the reaction of CK/SD/6 virus with C/B3. Substitution of serine for asparagine at the same position (N145S) enables the CK/GX/10 to react with C/B3 in hemaglutinin inhibition, immunofluorescence and neutralization assays. We further demonstrated that the amino acid N145 in the H9 HA protein is glycosylated. Our results provide experimental evidence that the glycosylation of HA oligosaccharide attachment sites implicated in antibody binding could have a role in antigenic variation.Biochemical and Biophysical Research Communications 07/2008; 371(1):168-71. · 2.48 Impact Factor -
Article: A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice.
[show abstract] [hide abstract]
ABSTRACT: In this study, we explored the molecular basis determining the virulence of H5N1 avian influenza viruses in mammalian hosts by comparing two viruses, A/Duck/Guangxi/12/03 (DK/12) and A/Duck/Guangxi/27/03 (DK/27), which are genetically similar but differ in their pathogenicities in mice. To assess the genetic basis for this difference in virulence, we used reverse genetics to generate a series of reassortants and mutants of these two viruses. We found that a single-amino-acid substitution of serine for proline at position 42 (P42S) in the NS1 protein dramatically increased the virulence of the DK/12 virus in mice, whereas the substitution of proline for serine at the same position (S42P) completely attenuated the DK/27 virus. We further demonstrated that the amino acid S42 of NS1 is critical for the H5N1 influenza virus to antagonize host cell interferon induction and for the NS1 protein to prevent the double-stranded RNA-mediated activation of the NF-kappaB pathway and the IRF-3 pathway. Our results indicate that the NS1 protein is critical for the pathogenicity of H5N1 influenza viruses in mammalian hosts and that the amino acid S42 of NS1 plays a key role in undermining the antiviral immune response of the host cell.Journal of Virology 03/2008; 82(3):1146-54. · 5.40 Impact Factor -
Article: Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.
[show abstract] [hide abstract]
ABSTRACT: H5N1 influenza viruses have caused significant disease and deaths in various parts of the world in several species, including humans. Vaccination combined with culling can provide an attractive method for outbreak containment. Using synthesized oligos and overlapping extension PCR techniques, we constructed an H5 HA gene, optiHA, containing chicken biased codons based on the HA amino acid sequence of the highly pathogenic H5N1 virus A/goose/Guangdong/1/96 (GS/GD/96). The optiHA and wild-type HA genes were inserted into plasmids pCI or pCAGGS, and designated as pCIoptiHA, pCAGGoptiHA, pCIHA and pCAGGHA, respectively. To evaluate vaccine efficacy, groups of 3-week-old specific pathogen free (SPF) chickens were intramuscularly injected with the four plasmids. Sera were collected on a weekly basis post-vaccination (p.v.) for hemagglutination inhibition (HI) assays and neutralization (NT) antibody detection. All chickens receiving pCAGGoptiHA and pCAGGHA developed high levels of HI and NT antibodies at 3 weeks p.v., and were completely protected from lethal H5 virus challenge, while only partial protection was induced by inoculation with the other two plasmids. A second experiment was conducted to evaluate if a lower dose of the pCAGGoptiHA vaccine could be effective, results indicated that two doses of 10 microg of pCAGGoptiHA could induce complete protection in chickens against H5 lethal virus challenge. Based on our results, we conclude that construction optimization could dramatically increase the H5 HA gene DNA vaccine efficacy in chickens, and therefore, greatly decrease the dose necessary for inducing complete protection in chickens.Antiviral Research 10/2007; 75(3):234-41. · 4.30 Impact Factor
Top co-authors
Top Journals
Institutions
-
2011
-
The University of Tokyo
- Institute of Medical Science
Tokyo, Tokyo-to, Japan
-
-
2005–2011
-
Harbin Veterinary Research Institute
Harbin, Heilongjiang Sheng, China
-
-
2006
-
Government of the People's Republic of China
Beijing, Beijing Shi, China
-
